GlassScriptPhysician profile
Caroline Marcia Ford
NPI 1427673748
$1,871.49
in general payments reported to CMS, 2019-2025
23 companies · $31.40 in 2025
The $31.40 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,050 · 2024: $790 · 2025: $31.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $251.63 | 2023-2024 | Ultomiris |
| Argenx US, INC. | $208.67 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $178.07 | 2023-2024 | Rystiggo, Zilbrysq |
| Tanabe Pharma America, INC. | $171.92 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $169.81 | 2023-2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $127.65 | 2023-2024 | Hyqvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.88 | 2024 | Jardiance |
| Ipsen Biopharmaceuticals, INC | $107.21 | 2023-2024 | Dysport |
| Otsuka America Pharmaceutical, INC. | $90.56 | 2023 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $74.44 | 2023-2024 | Ingrezza, Ongentys |
| Amylyx Pharmaceuticals, INC. | $57.83 | 2023 | Relyvrio |
| Merz Pharmaceuticals, LLC | $48.66 | 2023-2024 | Xeomin |
| Sk Life Science, INC. | $33.87 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $31.40 | 2025 | Imcivree |
| Csl Behring | $28.86 | 2024 | Hizentra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $27.25 | 2023 | Skyclarys |
| Axsome Therapeutics, INC. | $25.66 | 2024 | Auvelity |
| Azurity Pharmaceuticals, INC. | $24.72 | 2024 | Zonisade |
| Pfizer INC. | $21.89 | 2024 | |
| Acrotech Biopharma INC. | $20.12 | 2024 | Beleodaq |
| Alnylam Pharmaceuticals INC. | $16.36 | 2023 | Onpattro |
| Inspire Medical Systems, INC. | $15.51 | 2023 | Inspire |
| Medicomp INC | $14.52 | 2023 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.